UNION CITY, Calif., Oct. 21, 2008 (GLOBE NEWSWIRE) -- Questcor Pharmaceuticals, Inc. (NasdaqCM:QCOR - News) today announced that it will release financial results for the third quarter ended September 30, 2008 on Thursday, October 30, 2008 after the market close. The Company will host a conference call and webcast on Thursday, October 30, 2008 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the Company's third quarter and current corporate developments. The dial-in number for the conference call is 800-257-6607 for domestic participants and 303-262-2130 for international participants.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will be available for seven days. This replay can be accessed by dialing 800-405-2236 for domestic callers and 303-590-3000 for international callers, both using passcode 11120825#. To access the live webcast of the call, go to Questcor Pharmaceuticals' website at http://www.questcor.com. An archived webcast will also be available at http://www.questcor.com.

About Questcor

Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets two commercial products, H.P. Acthar(r) Gel (``Acthar'') and Doral(r). Acthar (repository corticotropin injection) is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis (``MS''). In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms (``IS''), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. Doral is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The Company is also developing QSC-001, a unique orally disintegrating tablet formulation of hydrocodone bitartrate and acetaminophen for the treatment of moderate to moderately severe pain. For more information, please visit http://www.questcor.com.

          Questcor Pharmaceuticals, Inc.
          Don Bailey
          510-400-0776
          dbailey@Questcor.com

          EVC Group, Inc.
          Investors
          Doug Sherk 
            415-896-6820 
          Dahlia Bailey
            415-896-5862
          Media
          Steve DiMattia
            646-201-5445